Related Experiment Videos

Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease

Samy I McFarlane1, Ashok Kumar, James R Sowers

  • 1Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, State University of New York, Health Science Center at Brooklyn, Brooklyn, New York 11203, USA.

The American Journal of Cardiology
|June 24, 2003
PubMed

Insights

Angiotensin-converting enzyme (ACE) inhibitors are vital for managing hypertension, diabetes, and cardiometabolic syndrome. These drugs help prevent complications, improve insulin sensitivity, and reduce the risk of developing type 2 diabetes.

Area of Science:

  • Cardiology
  • Endocrinology
  • Nephrology

Background:

  • Angiotensin-converting enzyme (ACE) inhibitors are primary treatments for hypertension in patients with cardiometabolic syndrome and diabetes.
  • These agents mitigate microvascular and macrovascular complications in diabetes and enhance insulin sensitivity.
  • ACE inhibitors show promise in preventing type 2 diabetes in hypertensive individuals with insulin resistance.

Purpose of the Study:

  • To explore the mechanisms by which ACE inhibition may prevent diabetes development.
  • To investigate how ACE inhibitors improve cardiovascular disease (CVD) risk markers.
  • To examine the role of ACE inhibitors in reducing CVD, renal disease progression, and stroke.

Main Methods:

  • Review of recent clinical studies and scientific literature.
  • Analysis of mechanisms underlying ACE inhibitor effects on glucose metabolism and insulin sensitivity.
  • Evaluation of impacts on vascular function, inflammation, oxidative stress, and thrombosis markers.

Main Results:

  • ACE inhibitor therapy is linked to reduced incidence of type 2 diabetes in hypertensive patients.
  • Improvements observed in vascular compliance, nitric oxide production, and inflammatory markers.
  • Demonstrated reduction in cardiovascular events, renal disease progression, and stroke incidence.

Conclusions:

  • ACE inhibition offers multifaceted benefits beyond blood pressure control.
  • Potential to prevent type 2 diabetes and reduce cardiovascular and renal complications.
  • Further research into mechanisms can optimize therapeutic strategies for high-risk populations.

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...